GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Awakn Life Sciences Corp (XCNQ:AWKN) » Definitions » EV-to-FCF

Awakn Life Sciences (XCNQ:AWKN) EV-to-FCF : -17.00 (As of Sep. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Awakn Life Sciences EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Awakn Life Sciences's Enterprise Value is C$4.08 Mil. Awakn Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2024 was C$-0.24 Mil. Therefore, Awakn Life Sciences's EV-to-FCF for today is -17.00.

The historical rank and industry rank for Awakn Life Sciences's EV-to-FCF or its related term are showing as below:

XCNQ:AWKN' s EV-to-FCF Range Over the Past 10 Years
Min: -31.4   Med: -2.14   Max: 8.01
Current: -21.25

During the past 4 years, the highest EV-to-FCF of Awakn Life Sciences was 8.01. The lowest was -31.40. And the median was -2.14.

XCNQ:AWKN's EV-to-FCF is ranked worse than
100% of 399 companies
in the Biotechnology industry
Industry Median: 8.13 vs XCNQ:AWKN: -21.25

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-21), Awakn Life Sciences's stock price is C$0.11. Awakn Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2024 was C$-0.130. Therefore, Awakn Life Sciences's PE Ratio for today is At Loss.


Awakn Life Sciences EV-to-FCF Historical Data

The historical data trend for Awakn Life Sciences's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Awakn Life Sciences EV-to-FCF Chart

Awakn Life Sciences Annual Data
Trend Jan21 Jan22 Jan23 Jan24
EV-to-FCF
- -4.91 -2.98 -2.41

Awakn Life Sciences Quarterly Data
Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.18 -3.03 10.58 -2.41 -28.31

Competitive Comparison of Awakn Life Sciences's EV-to-FCF

For the Biotechnology subindustry, Awakn Life Sciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Awakn Life Sciences's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Awakn Life Sciences's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Awakn Life Sciences's EV-to-FCF falls into.



Awakn Life Sciences EV-to-FCF Calculation

Awakn Life Sciences's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=4.081/-0.24
=-17.00

Awakn Life Sciences's current Enterprise Value is C$4.08 Mil.
Awakn Life Sciences's Free Cash Flow for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.24 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Awakn Life Sciences  (XCNQ:AWKN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Awakn Life Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.11/-0.130
=At Loss

Awakn Life Sciences's share price for today is C$0.11.
Awakn Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Apr. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.130.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Awakn Life Sciences EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Awakn Life Sciences's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Awakn Life Sciences Business Description

Traded in Other Exchanges
Address
301?217 Queen Street West, Toronto, ON, CAN, M5V 0R2
Awakn Life Sciences Corp is a clinical-stage biotechnology company intended to develop therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder. The Company focuses on Alcohol Use Disorder (AUD), a condition affecting the people in the US and key international markets and many people globally for which the current standard of care is inadequate, enabling to provide breakthrough therapeutics to addiction sufferers in desperate need.

Awakn Life Sciences Headlines

No Headlines